Market Closed -
Other stock markets
|
Pre-market 01:32:01 am | |||
2.44 EUR | -3.75% | 2.443 | +0.12% |
Jun. 04 | Innate Pharma: positive data in mycosis fungoides | CF |
Jun. 04 | Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.87% | 212M | |
+49.41% | 56.95B | |
+41.65% | 40.26B | |
-6.72% | 39.32B | |
-5.96% | 28.37B | |
+12.99% | 26.45B | |
-19.82% | 19.41B | |
+32.35% | 12.54B | |
-0.08% | 12.15B | |
+25.18% | 12.21B |
- Stock Market
- Equities
- IPH Stock
- News Innate Pharma
- Innate Pharma S A : Goldman Sachs Starts Innate Pharma at Neutral With $4.75 Price Target